烟台东诚药业集团股份有限公司关于分拆所属子公司烟台蓝纳成生物技术股份有限公司至香港联合交易所有限公司主板上市的进展公告
Group 1 - The company, Yantai Dongcheng Pharmaceutical Group Co., Ltd., is proceeding with the spin-off of its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., for a listing on the main board of the Hong Kong Stock Exchange [2][3] - The board of directors and the company have approved the spin-off plan during meetings held on August 28 and September 15, 2025 [2] - On September 29, 2025, Lanacheng submitted its application for an initial public offering and listing on the Hong Kong Stock Exchange [3]